GSK touts Nucala data after COPD miss

Research published Monday found GlaxoSmithKline's asthma medicine Nucala to be more effective in reducing flare-ups of the lung condition than two rival drugs, a result the British pharma was quick to highlight after failing to convince regulators to expand Nucala's label last week.